Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3654 - Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combination with olaparib in patients with advanced solid tumors


08 Oct 2016


Poster Display


Andrés Poveda


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


A.M. Poveda1, A. Oaknin2, I. Romero1, A. Guerrero3, L. Fariñas Madrid4, A. Soto5, C. Peris6, J.A. Lopez Guerrero7

Author affiliations

  • 1 Oncogyn Department, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 2 Na, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 3 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46008 - Valencia/ES
  • 4 Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 5 Clinical Research, PhamaMar, 28770 - Madrid/ES
  • 6 Data Center, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 7 Laboratory Of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES


Abstract 3654


PM01183 is a new anticancer drug that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Recently a significant activity in platinum-resistant ovarian cancer patients in terms of Response Rates (RR), has been reported (Poveda A et al. ASCO 2014.abstr #5505). PM01183 is currently being studied in different solid tumors. Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose [poly (ADP ribose] polymerisation (PARP) inhibitor (PARP-1,-2 and-3) with proven antitumoral activity in homologous recombination deficient (HRD) tumors. Olaparib is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. The combination of PM01183 and Olaparib has shown synergistic activity in cell-lines independent of HRD status.

Trial design

This first-in-human phase I-II study evaluates the safety and tolerability of PM1183 in combination with short course of Olaparib through a 3 + 3 dose escalation design Selection of patients: Phase-I patients with advanced or metastatic solid tumors without established standard therapeutic alternatives. Phase-II expansion cohort: platinum-resistant ovarian cancer patients (epithelial non-mucinous), triple negative breast and endometrial cancer patients. For patients included in the phase-II part of the study, evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be required. Primary endpoints are Phase-I: safety (MTD, DLT and RP2D); Phase-II: overall response rate. Secondary enpoints: Progression Free survival, Overall survival, PK and pharmacodynamic profiles, safety profile. Additional translational research to analyze predictive factors to further select potential candidates will be explored. The trial is in progress; 13 of up to 48 planned pts in the phase-I part have been recruited at the end of April 2016 (enrollment started Nov 2015).

Clinical trial identification


Legal entity responsible for the study



Pharmamar, AstraZeneca


A.M. Poveda: Roche, AstraZeneca, Pharmamar, Clovis Advisor. A. Oaknin: Roche, AstraZeneca, Clovis Advisor. A. Soto: Pharmamar employee and market share owner. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings